蛋白磷酸酶pp6调控调节性T细胞代谢重塑在高血压肾损伤中的作用机制
批准号:
82070509
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
李群
依托单位:
学科分类:
循环系统感染和免疫相关疾病
结题年份:
2024
批准年份:
2020
项目状态:
已结题
项目参与者:
李群
中文摘要
调节性T细胞(Tregs)在高血压肾损伤中作用关键,代谢重编程调控其功能,而如何启动Tregs代谢模式变化的内在机制尚不清楚。近期我们发现:血管紧张素II诱导高血压肾损伤中pp6病理性低表达,基因剔除pp6抑制Tregs分化和免疫抑制功能并偶联代谢模式从氧化磷酸化向糖酵解转变,加重肾损伤;pp6与线粒体功能蛋白Tid1的去磷酸化相关联;原创性肽miPEP31靶向上调pp6。推测pp6低表达减弱Tid1去磷酸化致线粒体功能受损,驱动Tregs代谢模式的改变参与调控生物学功能。因此,本项目拟以Tregs能量代谢模式为切入点探索:1、pp6去磷酸化Tid1调控线粒体功能的生化基础;2、Tid1调节Tregs代谢重编程和功能在高血压肾损伤中的机理;3、miPEP31治疗高血压肾损伤的效果及机制。明晰去磷酸化酶、代谢重塑、miPEP31、肾纤维化之间的关系,为逆转高血压肾损伤提供新思路。
英文摘要
Regulatory T cells (Tregs) play an important role in hypertensive renal injury, and metabolic reprogramming regulates the immunosuppressive function of Tregs, however, the underlying regulators of the metabolic reprogramming of Tregs remain unclear. Our recent studies found that: The expression of pp6 was pathologically decreased in Angiotension II (Ang II)-induced hypertensive injury renal tissues, and the genetic deletion of pp6 not only inhibited Tregs differentiation and immunosuppressive function but also undergoesed a shift from oxidative phosphorylation to aerobic glycolysis, and aggravated renal injury. We further found pp6 was associated with dephosphorylation of mitochondrial functional protein Tid1, the peptide miPEP31 identified by our group upregulated pp6. It is speculated that the loss of pp6 in Tregs attenuates the dephosphorylation of Tid1, resulting in impaired mitochondrial function, driving the metabolic alteration of Tregs and participating in the regulation of the biological function of Tregs. Therefore, taking the energy metabolism patteren of Tregs as the pointcut, our project intends to investigate: 1. Biochemical mechanism of pp6-mediated Tid1 dephosphorylation on mitochondrial function and metabolism; 2. The role of Tid1-mediated Tregs metabolic reprogramming and immunosuppression in hypertensive renal injury; 3. Whether miPEP31 harbours a therapeutic potential in hypertensive renal injury. This study would elucidate the relationship among phosphatase, metabolic remodeling, miPEP31, renal fibrosis. Taken together, these findings may provide a new target for the prevention and treatment of renal injury in hypertension.
背景:前期研究发现miR-31靶向pp6调节Treg细胞,是高血压治疗新靶点。调节性T细胞(Tregs)在高血压肾损伤中作用关键,代谢重编程调控其功能,而如何启动Tregs代谢模式变化的内在机制尚不清楚。本项目拟以对Tregs的功能及代谢模式的调控为切入点探索:1、pp6对Treg 细胞功能的调控在炎症发生进程中的具体分子机制机制;2、pp6通过介导Treg 细胞代谢模式的调控在高血压肾损伤中的作用机理;3、miPEP31对miR-31/ Treg细胞轴及高血压肾损伤的治疗效果和调控机制。..方法:本研究采用已经构建的FoxP3+ T细胞特异性敲除pp6小鼠(pp6-cKO)和miPEP31点突变(miPEP31-/-)等系列小鼠, AngII微量泵灌注诱导高血压肾损伤;尾动脉套管法测定血压;肾脏组织切片进行H&E和 Masson 染色;WB、ELISA及FACs检测各目标蛋白表达;海马生物能量测定仪 XF24, 分别检测细胞的细胞外液酸化率(ECAR)和糖酵解的储备能力、细胞的氧消耗率(OCR)和线粒体储备能力;透射电镜观察 Treg 细胞中线粒体的结构和功能变化;蛋白免疫印迹实验(Co-IP)及Phos-tag SDS-PAGE实验,明确 pp6 与 Tid1关系;细胞转染;外源尾静脉注射给予miPEP31。..结果:目前研究结果发现: 1)pp6调控DNMT1去磷酸化及AKT信号而作用Treg 细胞,有效缓解炎症发生(Gnens & Diseases,2022, 通讯作者);2)miR-31靶向E2F6调节内皮细胞凋亡,调控高血压病程(Biochem Biophys Res Commun, 2023, 通讯作者); 3)miR-31前体编码肽miPEP31,选择性降低miR-31表达促进Treg细胞分化,维持机体免疫平衡(EMBO Reports,2022,共同通讯);4)miPEP31竞争CEBP-α绑定miR-31启动子,调控miR-31/Treg轴,有效缓解高血压肾损伤(Cardiovascular Diabetology , 2024,通讯作者), 并获得一项已授权发明专利;..结论:阐明 miPEP31-miR31--pp6/Tid1-Treg 细胞代谢/功能- 肾脏损伤等炎症之间的关系,为治疗高血压肾损伤提供新靶点及研发原创多肽类药物提供新思路。
CCR6/Mip-3α轴在动脉粥样硬化发病中的作用及机制研究
-
批准号:81202298
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2012
-
负责人:李群
-
依托单位:
国内基金
海外基金